<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4711">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04748536</url>
  </required_header>
  <id_info>
    <org_study_id>C1104-003</org_study_id>
    <nct_id>NCT04748536</nct_id>
  </id_info>
  <brief_title>Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel Group Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of IRL201104 to Support a Future COVID-19 Patient Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune Regulation Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immune Regulation Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and pharmacokinetics of&#xD;
      repeat doses of IRL201104 given to healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">April 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with TEAEs and number of events will be summarised by treatment</measure>
    <time_frame>33 (group 1) or 35 (group 2) days</time_frame>
    <description>Adverse Events after treatment administration will be collected at baseline and repeated until study completion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with potentially clinically important (PCI) abnormal haematology variables will be summarised by treatment</measure>
    <time_frame>19 (group 1) or 21 (group 2) days</time_frame>
    <description>Haemoglobin, haematocrit, MCV, MCH, MCHC, RBC, WBC and differentials will be collected at baseline and after dose administration and repeated until Day 19 or 21</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with PCI abnormal clinical chemistry variables will be summarised by treatment</measure>
    <time_frame>19 (group 1) or 21 (group 2) days</time_frame>
    <description>Creatinine, glucose, triglycerides, urea, uric acid, bilirubin, cholesterol, sodium, potassium, alkaline phosphatase, AST, ALT and GGT will be collected at baseline and after dose administration and repeated until Day 19 or 21</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with PCI and/or abnormal electrocardiogram variables will be summarised by treatment</measure>
    <time_frame>19 (group 1) or 21 (group 2) days</time_frame>
    <description>RR, PR, QRS, QT-interval, QTcF and heart rate will be collected at baseline and after dose administration and repeated until Day 19 or 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with PCI abnormal vital sign variables will be summarised by treatment</measure>
    <time_frame>19 (group 1) or 21 (group 2) days</time_frame>
    <description>Blood pressure, pulse rate, oral body temperature and respiration rate will be collected at baseline and after single and multiple dose administration and repeated until Day 19 or 21</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of IRL201104: Trough blood concentration (Ctrough)</measure>
    <time_frame>5 (group 1) or 7 (group 2) days</time_frame>
    <description>Ctrough will be measured after multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of IRL201104: Maximum (peak) blood concentration (Cmax)</measure>
    <time_frame>5 (group 1) or 7 (group 2) days</time_frame>
    <description>Cmax will be calculated after multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of IRL201104: Terminal half life (t1/2)</measure>
    <time_frame>5 (group 1) or 7 (group 2) days</time_frame>
    <description>t1/2 will be calculated after multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of IRL201104: Area under the curve from time zero to last quantifiable concentration of IRL201104 (AUCt)</measure>
    <time_frame>5 (group 1) or 7 (group 2) days</time_frame>
    <description>AUCt will be calculated after multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of IRL201104: Apparent total body clearance from blood (CLss)</measure>
    <time_frame>5 (group 1) or 7 (group 2) days</time_frame>
    <description>CLss will be calculated after multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of IRL201104: steady state volume of distribution (Vz)</measure>
    <time_frame>5 (group 1) or 7 (group 2) days</time_frame>
    <description>Vz will be calculated after multiple dosing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Group 1: Dose A IRL201104 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IRL201104 IV once daily for 5 days OR Placebo IV once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Dose B IRL201104 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IRL201104 IV once daily for 7 days OR Placebo IV once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IRL201104</intervention_name>
    <description>lyophilised powder for reconstitution for IV dosing</description>
    <arm_group_label>Group 1: Dose A IRL201104 or placebo</arm_group_label>
    <arm_group_label>Group 2: Dose B IRL201104 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for IRL201104</description>
    <arm_group_label>Group 1: Dose A IRL201104 or placebo</arm_group_label>
    <arm_group_label>Group 2: Dose B IRL201104 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects age 18 to 65 years of age, and in good health as&#xD;
             determined by medical history, physical examination, vital signs, electrocardiogram,&#xD;
             and laboratory tests.&#xD;
&#xD;
          -  Female subjects agree to use highly effective contraception or be of non-childbearing&#xD;
             potential.&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          -  Able to communicate well with the Investigator/designee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known reaction to study drug or components&#xD;
&#xD;
          -  concurrent or recent infection or clinically significant conditions that may place&#xD;
             subject at risk or interference with absorption, distribution or excretion of drugs&#xD;
&#xD;
          -  No QTcF interval ≥450 milliseconds, no QRS complex ≥120 milliseconds, at Screening&#xD;
&#xD;
          -  Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus&#xD;
             antibodies (HCVAb) or human immunodeficiency virus (HIV) 1 and/or -2 antibodies at&#xD;
             Screening.&#xD;
&#xD;
          -  Excessive use of caffeine-containing beverages&#xD;
&#xD;
          -  Urinary cotinine level indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine containing products within 6 months before screening.&#xD;
&#xD;
          -  Presence or history of drug of alcohol abuse.&#xD;
&#xD;
          -  Positive screen for drugs-of-abuse or cotinine.&#xD;
&#xD;
          -  Blood donation in excess of 500mL within 3 months.&#xD;
&#xD;
          -  Participation in another clinical study with licensed or unlicensed study drug within&#xD;
             3 months of first IMP administration.&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities within 12 months before the first IMP&#xD;
             administration.&#xD;
&#xD;
          -  Use of live vaccine 28 days before dosing with study drug until telephone follow-up&#xD;
             and use of killed vaccine (including COVID-19 vaccine) 14 days before dosing with&#xD;
             study drug until telephone follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Immune Regulation</last_name>
    <phone>+1 (800) 689-7034</phone>
    <email>nancy.vinh@immuneregulation.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahiro Yamamoto</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

